According to a study funded by Novo Nordisk involving 3,533 patients globally, the breakout weight-loss drug marketed as Ozempic and Wegovy reduced the risk of kidney failure, loss of kidney function, and death in people with type 2 diabetes and chronic kidney disease by 24% compared to placebo.
Novo Nordisk's GLP-1 agonist semaglutide, marketed as Wegovy, reduced the risk of death by 20% in patients with type 2 diabetes and kidney disease, according to new peer-reviewed data.
The FDA recently expanded the approved use of Novo Nordisk's Wegovy after another successful clinical trial, highlighting the need for effective treatments.
Patients receiving Ozempic had lower risks of major heart events and death compared to those on a placebo, but withdrawal from the study, mostly due to gastrointestinal issues, was slightly higher in the Ozempic group.
Novo Nordisk and rival Eli Lilly aim to expand insurance coverage of their weight-loss drugs, including Ozempic, by demonstrating additional medical benefits.
This article was written in collaboration with Generative AI news company Alchemiq
Sources: Washington Post, Reuters, Daily Mail, New York Times, National Tribune, Quartz, Nature